Albert David (ALBERTDAVD)
Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹812.5 |
| Market Cap | ₹463.71 Cr |
| P/E Ratio | 42.28 |
| ROCE | 6.45% |
| ROE | 2.33% |
| Dividend Yield | 0.62% |
| Profit Growth | 303.1% |
| Debt/Equity | 0.08 |
| Sales Growth | 43.6% |
| Promoter Holding | 62.24% |
| 52-Week Range | ₹579.9 — ₹931.85 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹686.04 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
When I look at Albert David, I see a small pharmaceutical company selling at nearly its book value—price ₹717.55 against book value ₹725.05. That alone is interesting to a Graham disciple. But value investing is not just buying cheap assets; it is buying assets that can earn a satisfactory return. Here the historical scorecard is weak: ROE is just 2.33% and ROCE only 6.45%. You are paying almost book for a business that has not yet proven it can generate high returns on that book.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer